Keyword: Copaxone

A judge ruled that Teva must face a lawsuit alleging employment discrimination in September, and now jurors ordered the company to pay $6.3 million.

Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.

Teva lost a patent appeal for multiple sclerosis blockbuster Copaxone, a drug that has seen a considerable sales decline due to generics.

Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.

Teva is cutting its debt load, but a successful turnaround rests on its new products and late-stage pipeline, analysts say.

Over the last few years, the multiple sclerosis field has been a hotbed for formulary management. But that’s changed a bit in 2018.

Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.

Mylan may have cut the list price on its Copaxone copy, but the Israeli drugmaker says it’s still on track to rake in significant 2018 sales.

Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.

Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads.